67 Prevention of rheumatoid arthritis Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference ADJUST study - UA - ≤3 criteria for RA - Clinical synovitis - ACPA positivity - Symptoms <18 months 56 patients 26 treatment vs 24 placebo 8 infusions of 10 mg/kg of abatacept (10 mg/kg) for 6 months - 6 months - 1 year - 2 years - RA progression as per 1987 ACR criteria at 1 year - Radiographic assessment of hands/wrists and feet at 6 months, 1 and 2 years - MRI of hand/wrists at 2 weeks, 6 months, and 1 year - ACPA and RF levels at 6 months and 1 year - DAS28 score based on CRP levels - Swollen and tender joints (28-joint count) - Decreased but not significant RA progression in treatment group (46.2%) vs placebo (66.7%) - Improved osteitis, erosion, and synovitis at 6 and 12 months in treatment vs worsening of scores in placebo - Decreased ACPA positivity at 6 months (90.9%) and 1 years (86.7%) - DAS28-defined remission at 6 months (71.4% vs 35%) and 1 year (47.4% vs 27.4%) - Higher percentage of patients without swollen cells at 6 months (62.5% vs 14%) and 1 year (30% vs 14%) [57,58] 4
RkJQdWJsaXNoZXIy MTk4NDMw